Skip to main content
SUZ
NYSE Manufacturing

Suzano 3Q26 Net Income R$2.08B as Arbex Tissue Deal Reshapes Segments

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Industrial
Sentiment info
Neutral
Importance info
7
Price
$9.5
Mkt Cap
$11.982B
52W Low
$7.555
52W High
$11.535
52W Position info
26% above low
Off High info
18% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

SUZ sits 26% above its 52-week low of $7.555.

Summary

Suzano reported 3Q26 net income of R$2.08 billion on net sales of R$16.5 billion, the first quarter including the acquired Kimberly-Clark tissue business, now reported as a separate Consumer Goods segment. Nine-month Adjusted EBITDA fell to R$15.0 billion from R$16.2 billion a year earlier.


Key Events · Earnings and Guidance · SUZ

  • 3Q26 Net Income R$2.08 Billion

    Third-quarter net sales rose to R$16,515,544 thousand from R$12,153,145 thousand a year earlier, and net income attributable to controlling shareholders was R$2,103,937 thousand versus R$1,953,516 thousand in 3Q25.

  • Nine-Month EBITDA Down to R$15.0 Billion

    9M26 Adjusted EBITDA was R$14,958,937 thousand versus R$16,153,488 thousand in 9M25, with Pulp at R$13,257,622 thousand and the new Consumer Goods segment at R$961,675 thousand. Nine-month net income fell to R$8,203,412 thousand from R$13,321,518 thousand.

  • Arbex Tissue Deal Consolidated From July 1

    Suzano paid US$1,293 million (R$6,717 million) for 51% of FamPro Tissue Holdings (Arbex) plus a call option on the remaining 49%; the business added R$4,212,359 thousand of 3Q26 net revenue but a net loss of R$67,246 thousand after R$305,870 thousand of purchase-price amortization.

  • Tax Contingencies Jump to R$10.3 Billion

    Possible-loss income tax exposures rose to R$10,338,403 thousand from R$4,559,801 thousand at year-end, including a R$5,255,629 thousand assessment on Austrian subsidiary profits received in April 2026; total possible-loss contingencies are R$18,959,203 thousand.


Analysis · SUZ · Manufacturing

The first set of results with the Kimberly-Clark tissue business inside the perimeter reveals the shape of the new company. Third-quarter net sales jumped to R$16.5 billion from R$12.2 billion a year earlier, yet the acquired Consumer Goods segment contributed only R$961.7 million of Adjusted EBITDA against R$5.2 billion of cost of sales in the quarter, and purchase-price amortization pushed it to a small net loss. Group Adjusted EBITDA for the nine months fell to R$15.0 billion from R$16.2 billion as pulp realizations weakened, while net income held up in the quarter at R$2.08 billion thanks to a R$2.5 billion net gain on derivatives and a R$3.1 billion FX gain over nine months. The balance sheet carries the deal: net debt is roughly R$77 billion against R$21 billion of cash and securities, non-controlling interest jumped to R$5.8 billion on Kimberly-Clark's 49% of Arbex, and possible-loss tax contingencies more than doubled to R$10.3 billion, including a R$5.3 billion Austria profit-tax assessment received in April 2026. The 4.0x net debt/EBITDA covenant on the R$6.8 billion term bank loans was met at quarter-end.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SUZ was trading at $9.50 on NYSE in the Manufacturing sector, with a market capitalization of approximately $12B. The 52-week trading range was $7.56 to $11.54. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SUZ - Latest Insights

SUZ
Nov 05, 2026, 6:23 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $9.39
Real-time Price: $9.10 info
Change: -$0.290 (-3%) info
Market Cap: $11.643B info
SUZ
Nov 05, 2026, 4:38 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $9.50
Real-time Price: $9.10 info
Change: -$0.400 (-4%) info
Market Cap: $11.643B info
SUZ
Aug 24, 2026, 5:00 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $9.07
Real-time Price: $9.10 info
Change: +$0.030 (+0.33%) info
Market Cap: $11.643B info
SUZ
Aug 12, 2026, 6:11 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $8.06
Real-time Price: $9.10 info
Change: +$1.04 (+13%) info
Market Cap: $11.643B info
SUZ
Jul 01, 2026, 6:04 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $7.59
Real-time Price: $9.10 info
Change: +$1.51 (+20%) info
Market Cap: $11.643B info